Phillyrin for COVID-19 and Influenza Co-infection: A Potential Therapeutic Strategy Targeting Host Based on Bioinformatics Analysis.
Phillyrin for COVID-19 and Influenza Co-infection: A Potential Therapeutic Strategy Targeting Host Based on Bioinformatics Analysis.
复制标题
DOI：
10.3389/fphar.2021.754241
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Liu X
中科院分区：
文献类型：
--
作者：
Lai Y;Han T;Lao Z;Li G;Xiao J;Liu X
背景：新冠肺炎和流感共流行的风险很高，迫切需要找到一种针对混合感染的治疗策略。此前的研究表明，连翘苷不仅能抑制两种病毒的复制，而且具有良好的抗炎作用，有望成为抗新冠肺炎和流感的候选化合物。目的：探讨连翘苷作为新冠肺炎和流感病毒混合感染候选化合物的可能性，并推测其潜在的调控机制。方法：运用生物信息学、网络药理学等一系列方法，对连翘苷在新冠肺炎和流感混合感染中的药理靶点、生物学功能、治疗机制等进行了解和表征，挖掘其治疗潜力。结果：我们揭示了连翘苷的潜在靶点、生物学过程、京都基因和基因组百科全书(KEGG)途径以及连翘苷抗新冠肺炎和流感联合感染的上游途径活性。我们构建了蛋白质-蛋白质相互作用(PPI)网络，鉴定了50个HUB基因，包括MMP9、IL-2、VEGFA、AKT和HIF-1A。此外，我们的研究结果表明连翘苷对新冠肺炎和流感混合感染的治疗与免疫平衡和低氧细胞因子风暴的调节有关，包括HIF-1信号通路、PI3K-Akt信号通路、RAS信号通路和T细胞受体信号通路。结论：首次揭示了连翘苷治疗新冠肺炎和流感混合感染的潜在靶点和生物学途径。这些发现应能解决未来世界面临的新冠肺炎和流感并存的紧迫问题，但未来还需要临床药物试验进行验证。
Background: The risk of co-epidemic between COVID-19 and influenza is very high, so it is urgent to find a treatment strategy for the co-infection. Previous studies have shown that phillyrin can not only inhibit the replication of the two viruses, but also has a good anti-inflammatory effect, which is expected to become a candidate compound against COVID-19 and influenza. Objective: To explore the possibility of phillyrin as a candidate compound for the treatment of COVID-19 and influenza co-infection and to speculate its potential regulatory mechanism. Methods: We used a series of bioinformatics network pharmacology methods to understand and characterize the pharmacological targets, biological functions, and therapeutic mechanisms of phillyrin in COVID-19 and influenza co-infection and discover its therapeutic potential. Results: We revealed potential targets, biological processes, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and upstream pathway activity of phillyrin against COVID-19 and influenza co-infection. We constructed protein–protein interaction (PPI) network and identified 50 hub genes, such as MMP9, IL-2, VEGFA, AKT, and HIF-1A. Furthermore, our findings indicated that the treatment of phillyrin for COVID-19 and influenza co-infection was associated with immune balance and regulation of hypoxia-cytokine storm, including HIF-1 signaling pathway, PI3K-Akt signaling pathway, Ras signaling pathway, and T cell receptor signaling pathway. Conclusion: For the first time, we uncovered the potential targets and biological pathways of phillyrin for COVID-19 and influenza co-infection. These findings should solve the urgent problem of co-infection of COVID-19 and influenza that the world will face in the future, but clinical drug trials are needed for verification in the future.
登录
查看更多内容
DOI：
10.3390/v13061062
发表时间：
2021-06-03
期刊：
Viruses
影响因子：
--
作者：
Callahan V;Hawks S;Crawford MA;Lehman CW;Morrison HA;Ivester HM;Akhrymuk I;Boghdeh N;Flor R;Finkielstein CV;Allen IC;Weger-Lucarelli J;Duggal N;Hughes MA;Kehn-Hall K
通讯作者：
Kehn-Hall K
影响因子：
3.9
作者：
Gao YL;Du Y;Zhang C;Cheng C;Yang HY;Jin YF;Duan GC;Chen SY
通讯作者：
Chen SY
DOI：
10.1016/s1473-3099(20)30650-2
发表时间：
2021-04
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Javelle E;Raoult D
通讯作者：
Raoult D
DOI：
10.1164/rccm.202005-1583oc
发表时间：
2020-09-15
影响因子：
24.7
作者：
McElvaney, Oliver J.;McEvoy, Natalie L.;McElvaney, Noel G.
通讯作者：
McElvaney, Noel G.
影响因子：
3.3
作者：
Qu, Huanhuan;Zhang, Yongmin;Sun, Wenji
通讯作者：
Sun, Wenji